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Abstract
Nuclear receptor tyrosine kinases (nRTKs) are aberrantly upregulated in many types of cancers, 
but the regulation of nRTK remains unclear. We previously showed androgen deprivation therapy 
(ADT) induces nMET in castration resistant prostate cancer (CRPC) specimens. Through gene 
expression microarray profiles reanalysis, we identified that nMET signaling requires ARF in 
CRPC in vivo Arf deficiency in Pten/Trp53 conditional knockout mouse model. Accordingly, 
aberrant MET/nMET elevation correlates with ARF in human prostate cancer (PCa) specimens. 
Mechanistically, ARF elevates nMET through binding to MET cytoplasmic domain to stabilize 
MET. Furthermore, carbon nanodots resensitize cancer cells to MET inhibitors through DNA 
damage response. The inhibition of phosphorylation by carbon nanodots was identified through 
binding to phosphate group of phosphory-tyrosine via computational calculation and experimental 
assay. Thus nMET is essential to precision therapy of MET inhibitor. Our findings reveal for the 
first time that targeting nMET axis by carbon nanodots can be a novel avenue for overcoming drug 
resistance in cancers especially prostate cancer.
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Introduction
Prostate cancer (PCa) is the second leading cause of cancer-related deaths among men in 
Western countries. Androgen deprivation therapy (ADT) is a standard therapy for the 
patients who have PCa at advanced stages including metastasis. However, relapse is 
frequently observed in patients as the castration resistant forms of PCa (CRPC), metastatic 
CRPC, and multiple drug resistance may develop after ADT (1–4). Clonal growth as a stem 
trait can be elevated in drug resistance during cancer evolution, suggesting a cause of the 
cancerous stem and the expansion of individual cancer cells (5). The signaling pathways that 
promote the clonal resistant stem cells to evade the drug treatment is still unclear, even there 
are some reports on the stem signaling crosstalk with drug efflux pumps such as ABC 
transporters (4, 6, 7).
Numerous studies revealed that aberrant activation of receptor tyrosine kinases (RTKs) 
regulates CRPC growth and drug resistance (8). For example, MET, especially nuclear form 
of MET (nMET) is associated with CRPC through cancer stem-like signaling including β-
catenin (9). As a receptor tyrosine kinase, the canonical MET, namely membrane MET 
(mMET or c-MET) is activated by HGF ligand which results in autophosphoylation at 
Y1234/Y1235 that provides a docking platform to recruit kinases, adaptors to further 
activate downstream signaling pathways such as AKT, β-catenin (10, 11). It has been shown 
that the nMET is increased in breast cancer cells upon cleavage (12), but the regulation of 
nMET is largely unknown. We recently found that nMET expression is correlated with 
CRPC growth in human PCa specimens (13). A few MET inhibitors such as crizotinib (14) 
have introduced to clinical trials but acquired drug resistance frequently develop in patients 
(15, 16). Therefore, targeting MET/nMET activators or crosstalk pathways would be more 
efficient to treat advanced PCa or CRPC.
ARF named as human p14ARF (or ARF) and mouse p19Arf, is an alternative transcript of 
ARF-INK4a locus on human chromosome 9q21 (17) with the canonical function of tumor 
suppression. However, ARF is frequently upregulated by oncogenic stimuli such as PTEN or 
TP53 mutation (18). Our previous work and some recent discovery indicate ARF may 
potentiate promoter function in tumor. For examples, ARF correlates with PTEN loss in 
human PCa specimens (18), promotes epithelial–mesenchymal transition (EMT) and 
microenvironmental invasiveness in PCa (19, 20), inhibits cell death (21), and functions as a 
tumor promoter upon nutrition depletion (22). In PCa, ARF is also elevated in many cancer 
cell lines (20). However, molecular mechanism of ARF in CRPC remains elusive.
Carbon nanodots (c-dots) derived from differential resources have been widely studied in 
imaging, drug delivery but less studied in intrinsic enzyme (nanozyme) activity, and 
mechanisms underlying the potential as anti-cancer agents (23). For example, food-derived 
c-dots have been found to be able to inhibit tumor growth in xenograft model (23). 
Previously, we found tea-derived c-dots can bind certain amino acids on ARF and colocalize 
with ARF in nucleus which sensitizes cancer cells to rapamycin (24,25). As the tea leaves 
derived c-dots are believed mainly contain carbohydrate along with some functional groups 
such as carbonyl or carboxylic acid, or both, other carbon sources should also be developed 
into carbon dots and the combination with facial modification through doping may bring 
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some special functions. Meanwhile, computational approaches have been introduced to 
simulate the interactions between nanomaterials and biomolecular systems (26). Dynamic 
simulation, although well represents the realities of the system, sacrifices some atomistic 
and/or molecular details, not to mention the high computation and time cost (27–28). Some 
computational simulations are aiming at the accurate estimation of the toxicity of 
nanomaterial or the electrostatic interaction between biomolecular systems and nanoparticles 
within a macroscopic dimension, wherein, the detailed such as the shape, size, surface 
distribution of functional groups about nanoparticles is rather important (29–30), whereas, in 
the study of drug delivery or other biomolecular mechanisms, the quantum mechanical 
model is based on the scaffold of the functional groups that well represent the chemical 
reactivity of the involved systems(31). In the present work, we reported soybean-derived 
carbon nanodots that inhibit ARF/MET pathways, and provided explanations on novel 
mechanisms of the combination therapy by performing quantum mechanical simulation. Our 
model revealed that the functional groups from both c-dots and phosphorylated tyrosine on 
nMET are critical for the enzyme activity of carbon nanodots through binding to phosphor 
groups.
Results
1. Array profiles re-analysis identified that p19Arf is required for nMET in castration 
resistant prostate tumor growth
Previously we showed that in genetic engineered mouse model of prostate cancer, generated 
by Pten/Trp53 double-mutant (referred to as Pten/Trp53), MET amplification is ranked as 
top elevated genomic changes (11). To further identify upstream pathways that regulate 
MET signaling, we applied gene expression profiles of microarray re-analysis using Pten/
Trp53/p19Arf triple-mutant mice as this type of mice dramatically deceased phenotype of 
tumorigenesis compared to Pten/Trp53 mice (20). We found many genes expressed 
differentially are related to MET signaling such as Muc20, Mapk13 (Figure 1A). The data 
suggest that ARF may crosstalk with MET pathways.
Then we tested whether Met involves in the p19Arf deficiency mediated tumor restriction. As 
shown in Figure 1B and S1, Met protein is highly expressed in prostate tumors of Pten/
Trp53 mice but not p19Arf deficient Pten/Trp53 mice. To be note, Met expression 
predominately localizes in plasma membrane in tumor cells of Pten/Trp53 mice. This is 
consistent with our previous findings (13, 19). Thus our data suggest that ARF may also 
regulate MET expression for tumor progression. We are attempted to further investigate 
whether ARF also contributes to CRPC in vivo. We examined the effects of p19Arf 
deficiency on the recurrent growth of prostate tumors in mice (Figure 1C). As shown, a 
complete loss of p19Arf decreased the recurrent growth of prostate tumors significantly in 
castrated Pten/Trp53 mice (Figure 1C). Moreover, IHC analysis revealed that p19Arf loss 
resulted in a decrease in the nucleus localization of Met in CRPC mice with elevated nuclear 
β-catenin (Figure 1D). Therefore, ARF correlates with CRPC and MET/nuclear MET 
(nMET)/ β-catenin signaling in vivo.
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2. ARF associates with nMET through cytoplasmic domain and correlates with nMET in 
human PCa specimens
Given the important roles of both ARF and MET in CRPC, we examined the association and 
correlation of ARF with nMET in both PCa cell lines and human specimens. To test whether 
ARF and MET interacts in nucleus, we first performed IF staining and found that ARF is co-
localized with MET in nucleus of PC3 and DU145 cells (Figure 2A and S2A). 
Immunoprecipitation (IP) analysis further showed that ARF physically binds with MET in 
nuclear extract of PC3 cells (Figure 2B). Finally, ARF or MET knockdown decreased PC3 
cell growth and co-knockdown both ARF and MET dramatically decreased cell growth 
(Figure 2C and S2B). Thus our data suggest that ARF interacts with MET, increases MET 
levels and promotes androgen insensitive PCa cell growth.
To further explore the binding mechanism between ARF and nMET, we applied truncated 
mutants to investigate the domains that mediated this event. We co-transfected cells with 
ARF and MET-GFP fusion mutant plasmids. As expected, without ARF, two distinct 
mutants either localize to nucleus or not nucleus (nucleus exclusion) (Figure 2D). We found 
ARF overexpression promotes nMET levels (Figure 2E). For nucleus- exclusion mutant, 
ARF elevation showed very limited effect on nMET levels (Figure 2E). Based on the mutant 
domain structures, it is quite clear that the nucleus translocation by ARF is predominately 
mediated by cytoplasmic domain. Consistent with the nMET levels enhanced by ARF, C4–
2B cell growth was promoted by nMET only upon ARF overexpression (Figure 2F). Hence 
ARF promotes nMET expression and cell proliferation not through kinase domain but 
through cytoplasmic domain.
Next, in prostate tissue microarrays analysis, it was observed that MET expression levels 
were significantly higher in both stage II and stage IV PCa samples, compared to normal 
tissues (Figure 2G-2I). Our results indicated that MET expression was positively correlated 
with the severity of advanced prostate cancer. The combined scores of IHC staining showed 
that ARF levels are positively correlated with MET especially nMET (Figure 2I). It was 
suggested that ARF and MET/nMET may crosstalk in driving advanced PCa.
3. MET requires ARF for turnover and recruitment of β-Catenin
First we found that acute ARF inactivation decreased MET expression upon a transient ARF 
knockdown in PC3 and DU145 PCa cells, two hormone insensitive cell lines (Figure 3A). 
Then we used Urea to disrupt the protein folding and found ARF knockdown decreased 
maturation of MET (Figure 3B). Further protein synthesis chase assay demonstrated ARF 
knockdown decreased MET half-life from 6hrs to 3hrs (Figure S3). Consistent with the 
protein degradation assay, MET Ubiquitination was reduced by ARF overexpression or 
enhanced by ARF knockdown (Figure 3C-D).
Previously we found nMET activates nuclear β-Catenin. In the present work, we found ARF 
knockdown enhanced membrane but reduced nuclear accumulation of β-Catenin (Figure 
3E). IP results convinced that ARF knockdown disrupted the recruitment of β-Catenin to 
MET (Figure 3F). To be noted, ARF knockdown led to a decrease of both MET and β-
Catenin expression in PC3 cells (Figure 3F). As nuclear β-Catenin is transcriptional active 
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and fast destructive, therefore β-Catenin nuclear accumulation promoted by ARF may 
contribute to ARF/MET signaling activation. Indeed, nMET destructs β-Catenin faster by 
protein synthesis chase assay (Figure 3G). In addition, MET/nuclear MET activates 
transcription of β-catenin target gene MMP7 (Figure 3H) and AR (13). Overall, our data 
suggest that ARF promotes recruitment of MET/nMET/β-Catenin for transcriptional 
regulation of downstream signaling targets genes.
4. nMET mediates drug resistance through DNA damage response
First, nMET accumulation was commonly observed in clonal tumors cells treated with MET 
inhibitor Crizotinib in Pten/Trp53 mouse tumors (data not shown). We then discovered that 
the PC3 cells treated by Crizotinib though experienced membrane MET loss, remained 
sustained or even elevated nMET with co-upregulation of ARF tested by different c-MET 
antibodies of C28 or D1C2. This suggests nMET mediates MET inhibitor drug resistance 
(Figure 4B). To exam whether nMET induction is related to DNA damage response with 
ARF, the DNA damage agent doxorubicin (DOX) was applied and the results showed that 
DOX also induced nMET depending on ARF and HSP90 suggesting that nMET induction is 
through folding and turnover (Figure 4C) which is consistent with above finding (Figure 
3B). Further tests indicated that ARF and MET co-knockdown enhanced the DNA damage 
which results in inhibition of cell growth (Figure 4 D). After all, MET requires ARF in 
insensitization to DNA damage drug. Moreover, the fact that ARF knockdown inhibited 
nMET accumulation upon Crizotinib treatment once again, emphasized ARF-dependence of 
nMET.
5. Androgen receptor interrupts ARF/MET axis
As AR plays essential roles in PCa and CRPC, we then attempted to exam the correlation 
among ARF, AR, and MET. It was discovered that MET correlates with ARF positively, but 
negatively with AR in PCa cell lines investigated (Figure 5A). Then androgen depletion was 
performed in LAPC4, an androgen sensitive and AR positive cell line, by treatment of 
charcoal striped FBS (cFBS). We found the androgen depletion led to the elevation of both 
ARF and MET, with nMET target SOX9 and β-catenin which are essential nMET targets 
(Figure 5B). Since nMET level is less in AR positive sphere cells but sustained with AR at 
extremely low level in non-sphere cells, the interaction and crosstalk between nMET and AR 
is likely weak (Figure 5C). It was noticed that ARF knockdown reduces cytosolic MET, 
SOX9 and β-catenin, that is to say, ARF does not directly promote nuclear translocation but 
rather do that through indirect cytosolic stabilization (Figure 5D). Moreover, activation of 
AR abolished the ARF knockdown effect on MET downregulation, suggesting AR interferes 
the ARF/MET axis (Figure 5E). This is consistent with the observation where AR 
overexpression in PC3 cells abolishes the interaction between ARF and MET (Figure 5F). 
AR also abolished ARF mediated androgen-independent cell growth in androgen insensitive, 
AR positive C4–2B cells (Figure 5G). Moreover, AR promoted mMET but not nMET 
mediated cell migration (Figure 5H). Further experiments indicated that AR correlates with 
DNA repair protein of nuclear BRCA1, however, ARF opposes nuclear BRCA1(Figure 5I-
J). In addition, ARF mediates ATM mediated DNA damage and PARP mediates DNA repair, 
while AR dysregulates the ARF mediated DNA damage response (Figure 5M). In 
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conclusion, ARF, AR, and MET may exert distinct signaling in CRPC by interfere or 
crosstalk.
6. nMET phosphorylation is sustained by ARF and is abolished by carbon nanodots
Complementary overexpression or knockdown of ARF effect on cell growth and invasion 
suggest that ARF cooperates with nMET but not significantly with mMET in cancer cells 
(Figure 6A-B). Moreover, nMET is a phosphorylated protein, the elevation of its 
phosphorylation depends on ARF, as ARF knockdown prevents MET phosphorylation in 
nucleus (Figure 6C-E). A novel treatment was then developed in the present work to prevent 
nMET phosphorylation. The carbon nanoparticles, with an average size of ~10 nm, derived 
from soybean, showed some impressive inhibition against nMET and its phosphorylation 
through direct binding to phosphorylated amino acid tyrosine (Figure 6F-G). The carbon 
nanodots derived from soybean inhibiting nMET and its phosphorylated form is then seen as 
a promising future cancer therapy.
7. Interaction between c-dots and phosphate anion
Atomic force microscopy result suggested that the synthesized carbon dots have an average 
size of 9 ± 2 nm. The FT-IR spectra of the C-dot is presented in the wavenumber range of 
900 cm−1 to 1900 cm−1, where nearly all the typical absorption bands for amide are 
emerged, among which we observed the peak at 1637 cm−1 representing the C=O stretching 
vibration in amide, the peak at 1540 cm−1 representing N-H bending vibration, and the peak 
at 1440 cm−1 representing C-N vibration. The bands at 2960 cm−1 and 3004 cm−1 
representing N-H stretching were also observed. The DNA gel electrophoresis test indicated 
the synthesized c-dots carry positive charge (data not shown) then we studied its binding to 
phosphor-group (Figure 6H-K). In the present work, we first confirmed its binding to 
phosphate acid (Figure 6H) then we tested the extracted the total protein from PC3 cells, by 
adding c-dots. The FTIR spectra in Figure 6J showed the addition of c-dots led to a 
suppression of the entire band centered at 980 cm-1.
In order to specify the interaction nature between c-dots and phosphate group, we 
synthesized phosphorylated tyrosine. The FT-IR spectra of phosphorylated tyrosine before 
and after adding c-dots were collected and compared as in Figure 6I. On both spectra, there 
are mainly three bands located at 1632 cm−1, 1072 cm−1, and 990 cm−1. The band at 1632 
cm−1 generally represents the C=O stretching vibration, whereas the other two bands can be 
assigned as out of phase O=P=O stretching mode ѵa(PO) (1072 cm−1) and in phase O=P=O 
stretching mode ѵs (PO) (990 cm−1) (32). It may be noticed the band at 990 cm−1 is very 
broad with a shoulder representing P-OH-H bending mode 𝛿 (POHH) for the phosphorylated 
tyrosine. This band is slimmed down with the disappearance of the shoulder upon addition 
of c-dots.
8. Carbon nanodots sensitize PCa cells to MET inhibitor
To further explore the potential treatment avenues using soybean c-dots targeting both ARF 
and MET, the c-dots effect on expression of ARF and MET levels was examined. The results 
showed that the application of c-dots to the system led to a decreased protein levels (data not 
shown). It was further discovered that c-dots induced DNA damage markers of γ-H2AX and 
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phosphor-ATR, DNA comet tails, as well as the ROS generation at dose of 0.1mg/ml (Figure 
7A-C). It was assumed that c-dots may target phosphor-nMET and inhibit its 
phosphorylation. Since MET inhibitor has less efficiency on nMET, we then combined c-
dots with MET inhibitor and higher efficiency was observed on DNA tails, ROS generation, 
the reduction of MET levels, and more cleaved PARP. The DNA damaged repair deficiency 
and cell growth inhibition in both PC3 and DU145 cells were achieved by drug combination 
through ubiquitination (Figure 7A-G). Figure 7H-I indicates DOX promoted the efficiency 
of MET inhibitor leading to the suppression of cancer cell growth. This implies that DNA 
damaging potentially crosstalk with MET inhibition pathways. Further analysis of DNA 
damage showed that the combination with c-dots enhanced MET inhibitor induced DNA 
damage and the repair response detected by markers of γ-H2AX and ATR (Figure 7I). More 
importantly, c-dots enhanced MET inhibitor sensitization requires the cooperation of ARF, 
as ARF overexpression can block the effect (Figure S4). Thus, targeting ARF/MET/nMET 
axis using unconventional green nanomaterials of carbon dots would be promising in 
prevention of drug resistance and CRPC cells growth simultaneously.
9. The calculated energies along with the vibrational spectra using a system made of 
protonated acetamide and the phosphorylated tyrosine
A quantum mechanical calculation was performed to simulate the interaction between 
carbon dots and phosphorylated tyrosine. The FT-IR spectrum of c-dots indicates the major 
functional group distributed on the surface of the carbon dots is amide group. Considering 
the fact c-dots carry positive charge, we use a protonated acetamide to represent c-dots. The 
calculated IR spectrum based on carbonyl oxygen protonated acetamide with a structure 
shown in Figure 6 K as AmH+(B) exhibits correspondence among quite a few bands, such 
as H-N-H bending vibration dominated band at 1637 cm−1, C-N-H bending dominated 
absorption at 1540 cm−1, and C-N stretching involved band at 1245 cm-1. The highly 
consistency between the FT-IR spectrum of c-dots and the calculated IR spectrum of 
protonated acetamide implies that protonated acetamide is representative at least with 
respect to the chemical reactivity of the c-dots.
The FT-IR spectrum of phosphorylated tyrosine represents a vibrational pattern of HPO42-, 
in other word, the phosphate group is monoprotonated (denoted as Tyr-OPO3H-) whose 
structure is displayed in Figure 8. The calculations on energetics were performed based on 
four fundamental structures established between (A). non-protonated acetamide and Tyr- 
Tyr-OPO3H- in Figure8 A; (B).protonated acetamide and Tyr-OPO3H-, where the involved 
oxygens on Tyr-OPO3H- are both not protonated(Figure 8B); (C). protonated acetamide 
and phosphorylated tyrosine, where the protonated C=O on acetamide interacts as a proton 
donor with the protonated P-O on Tyr-OPO3H- (Figure 8C); (D). protonated acetamide and 
Tyr-OPO3H-, where the protonated C=O on acetamide interacts as an electron lone pair 
donor with the protonated P-O on Tyr-OPO3H- (Figure 8D). Among the various 
interactions between actamide w/o protonation and Tyr-OPO3H-, structure in Figure 8B 
shows the most negative enthalpy change. The IR spectra corresponding to different 
interacting complexes are displayed in Figure 6H as the dished lines. Overall, the calculated 
vibrational patterns for the interacting complex 8B, 8C, 8D show certain consistency with 
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the experimental spectrum of phosphorylated tyrosine with the addition of c-dots in terms of 
in phase/ out of phase O=P=O stretching modes.
Most importantly, based on the calculation, we further found the carbon nanodots have 
intrinsic phosphatase-like activity by in vitro assay (Figure S6). Thus, our data suggest that 
soybean-derived carbon nanodots may function as a phosphatase or kinase inhibitor and 
through combination with specific kinase inhibitors, they may more specifically target 
kinases induced tumor growth especially resistant tumors.
Discussion
In this study, we elucidated for the first time that androgen deprivation activates ARF/MET//
nMET/β-Catenin pathway both in vitro and in vivo and a novel mechanism in which MET 
requires ARF to sustain nuclear oncogenic functions for PCa progression, at least in the 
context of PTEN/p53 loss. Nano carbon dots may be a potential avenue to disrupt the 
ARF/MET signaling and enhance the efficacy of MET inhibitor.
One of the important discoveries in this study is that MET in nucleus is sustained by ARF 
but disrupted by AR. Many studies suggested that MET in nucleus may play pivotal roles in 
oncogenic functions. Early studies showed that MET in nucleus promotes the cell 
proliferation in breast cancer (12) and nuclear reprogramming in PCa (13). Here we further 
observed that nuclear MET correlates with ARF in human PCa specimens and is stabilized 
by ARF, but is disrupted by AR through distinct DNA damage repair systems from ARF or 
AR. Given that both ARF and AR regulate each other’s expression or activity in PCa cells 
(26, 33), the feedback loop may be formed among ARF/MET/nMET/β-Catenin/AR. 
Nevertheless, whether, and why reactivated AR may in turn negatively regulates MET 
remains unclear. One of the possible mechanisms is the intrinsic protection to prevent further 
aggressive cancer development initiated by cell stress response. Recent studies showed that 
AR positively regulates ARF thus the dual positive feedback elevation of MET by both ARF 
and AR may be complementary or competitive inhibition. The detailed mechanisms is left 
for further investigation to elucidate the correlation of ARF/MET/nMET under low 
androgen condition.
In addition to its tumor suppressor function, emerging evidence revealed that the novel 
functions of ARF in cells and in mouse tissues depend solely on metabolisms and signaling 
pathways, but are independent of Mdm2-p53 pathway. It has been shown that ARF has the 
pro-proliferative or oncogenic-promoting roles in some cells under various contexts of 
physiological and genetic alterations such as nutrition depletion, the viability of meiotic 
germ cells, or PTEN loss (2, 20–22, 25). Similarly, the uncoupling scenario of p19Arf-p53 
upon oncogenic insults was found in Pten-deficient prostate tumorigenesis (2). These studies 
provided lines of genetic evidence that the activation of intact p53 signaling pathway plays 
critical roles in biological functions of ARF. Our findings demonstrated that ARF regulates 
MET in both mouse prostate tumors and PCa cells null for PTEN and p53 genes, a frequent 
event at the advanced stages of human prostate malignancy (34). Differential to its tumor 
suppressive role in glioma and melanoma (35), ARF regulates functions and transcriptional 
activation of oncogenic signaling events in nucleus of cancer cells through multiple 
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mechanisms (36). Thus the details in ARF transition from tumor suppressor to promoter 
deserve further investigation which may link aging to cancer transformation (37).
The interaction between phosphorylated tyrosine and c-dots becomes evident considering 
both the FT-IR experiment and quantum mechanical calculation results. In the FT-IR 
spectrum, the broad shoulder representing P-OH-H bending mode (POHH) on Tyr-OPO3H- 
disappeared once the c-dots were added in the system. On the other hand, the quantum 
mechanical calculation indicates the protonated acetamide (the protonation site is on C=O 
group) tends to have stronger interaction with Tyr-OPO3H- than the acetamide without 
protonation. It confirms the necessity of the positive charge on c-dots. The comparison of the 
experimental and calculated IR spectra implies the complexes formed between c-dots and 
phosphorylated tyrosine is likely a mixture of the structures shown in Figure 8B, 8C, and 
8D. This leads us to a realization that positive charged carbon nanodots can bind 
phosphorylated tyrosine and inhibit phosphorylation of nMET, and further promote MET 
inhibitor sensitization. Thus, c-dots can be used as targeting therapy as both a deliver/carrier 
and an anti-cancer drug. The dual role of c-dots is benefited from its higher toxicity than 
most types of nanoparticles. In the future, the conjugation of kinase inhibitors and c-dots 
holds huge potential in targeted inhibition of kinases.
Given that drug resistance frequently occur in cancer through multiple mechanisms, 
nanoparticles are the best drug delivery carrier as non-substrate of drug transporters, 
reversing resistance by nanoparticles have been acknowledged in preclinical or clinical 
studies (38). For example, milk-derived carbon nanoparticles with fabrication of doxorubicin 
through electrostatic interactions have been found to delivery DOX to nucleus and showed 
increased efficacy of DOX in cancer cells but less in normal fibroblast cells (39). Moreover, 
BYL719, a PI3Kα inhibitor conjugated with P-selectin-targeted nanoparticles, showed 
higher delivery efficiency to head and neck tumor (40). Compared to other nanoparticles, 
due to water soluble, biocompatibility, the potential of c-dots in drug delivery is promising if 
targeted into tumor cells.
However, if not targeted into ideal tumor tissues, the limitation of c-dots on drug delivery is 
obvious so that side effect may appear. As carbon materials are green materials to the 
microenvironment, compared to other metal related nanoparticles, carbon dots showed 
significant mild side effect on tissues. In cell level, based on our results and personal 
communication, food-derived c-dots can enter in to nucleus to abolish nuclear drug targets 
such as epigenetic factors, transcriptional events, DNA, nuclear RTK/MET kinase or other 
nuclear targets of prostate cancer such as YAP, AR (25). Therefore, more precision delivery 
should be designed as far as c-dots mediated drug delivery is concerned.
Most importantly, we provided experimental, conceptual and promising novel treatment 
avenue that using c-dots to enhance RTK inhibitor efficiency, which is the first report in the 
green carbon-drug field, though there is a report using gold nanoparticles conjugated with 
FLT3 kinase inhibitor in leukemia (41). Thus green carbon nanoparticles would provide a 
more ecologically benefit treatment for combinatorial therapy or drug delivery using RTK 
inhibitors.
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In summary, it is the first report on how nuclear RTKs can be sustained by a tumor 
suppressor for drug resistance. Our novel finding that androgen deprivation mediated 
ARF/MET/nMET/AR axis would provide the guidance for precision treatment. Moreover, 
ARF might be a pharma-marker for individual treatment with MET inhibitor. Finally, we 
provided a novel avenue using food-derived nanomaterials for CRPC treatment by targeting 
ARF/MET axis and overcoming drug resistance to MET inhibitor. Emerging data have 
shown that nMET is widely found in many types of cancer, thus c-dots based novel therapy 
might be broadly attractive for targeted precision cancer therapy (38–39,42–43). Moreover, 
in a broad concept, drug resistance to many kinase inhibitors often occurs through multiple 
mechanisms such as reactivation of crosstalk pathways or self-induction (44–45). For 
example, HGF ligand can activate MET inhibitor resistance, and MET elevation can 
resistant to EGFR inhibitor (44–45). Based on our finding, c-dots can bind phosphor-
tyrosine and may inhibit phosphorylation by physical occupying through electric statics 
which is a good events for protecting additional molecular binding or phosphorylation 
occurring. The carbon nanodots would have great application potential in preventing RTK 
inhibitor resistance. Thus conjugated carbon nanodots-RTK inhibitor compound would 
provide a novel avenue for targeted therapy in cancer for preventing drug resistance.
Materials and methods
1. Mutant mice, tumor analysis and microarray based pathway reanalysis
In accordance with and approved by IACUC guidelines at Meharry Medical College 
( MMC), the C57BL/6 knockout mice were bred and maintained at MMC animal core 
facility. Pten and Trp53 conditional knockout in prostates are controlled by Probasin-Cre 
recombination (18). All male, aged at 3months or 6 months of wild type (Wt), p19Arf 
knockout mice (p19Arf−/−), Pten/Trp53 double-mutant (referred to as Pten/Trp53), and Pten/
Trp53/p19Arf triple-mutant mice (referred to as Pten/Trp53/p19Arf) were generated and 
genotyped as described previously (18, 19). Sample numbers are indicated in figures. 
Sample sizes are collection of all mice which were generated in this specific experiment at 
the similar experimental period and without exclusion, without randomization, without 
blinding during the analysis were used. Tissues were fixed and processed and 5 μm thickness 
of tissue sections were applied for H&E and immunohistochemically (IHC) staining. For 
IHC analysis, sections were stained with antibodies: MET (C28, Santa Cruz), β-Catenin 
(1:100, Cell Signaling).
2. ARF knockdown by small hairpin RNA (shRNA), cell proliferation, drug response and 
cell invasion assays
p14ARF stable knockdown and scrambled control cell lines were established as described 
previously (19,46). For transient knockdown, shRNA constructs were transfected into cells, 
and cell lysates were collected and subjected to immunoblotting analysis after 48–72 hrs. 
For cell proliferation, cells were replated in 96-well plates at a density of 3000 cells per well. 
Cell numbers were determined at 2, 4, and 6 days by counting cell number or by WST-1 
assay based on commercial instructions (Roche). Alternatively, for drug response of cell 
growth assay, cells were seeded in 24-well plates at a density of 5×105 per well and 24hrs 
post-transfection, cells were treated with drugs indicated in figure legends, fixed, stained 
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with 0.3% crystal violet and counted through absorbance. For shRNA mediated cell growth 
inhibition assay, cells were transfected with scrambled or shARF plasmid using 
Lipofectamine 2000 or Lipofectamine 3000 (Life Technologies) or infected by lentivirus 
containing shRNA plasmid. For cytotoxicity assay, drugs including doxorubicin (DOX) or 
nanodots were used for treatment 24hrs post plating of cells and 3 days later, cells were 
fixed, stained with 0.3% crystal violet and counted through absorbance. For invasion assay, 
cells were cultured in 60mm Petri dishes until confluence. After starved for 16 hrs, cells 
were seeded at a density of 5×104 per well into the upper chamber with 8 μm polyethylene 
terephthalate membrane filters (Becton-Dickinson). Finally cells were fixed, stained with 
0.3% crystal violet and counted.
3. Immunofluorescence (IF), immunoblotting (IB) and co-immunoprecipitation (IP) assays
For IF analysis, cells were seeded on coverslips for 2 days and then fixed in 4% 
paraformaldehyde for 15 min. Antibodies for IF were: p14ARF monoclonal antibody (14P02, 
1:100, NeoMarkers, Catalog No.MS850P1 of Thermo Scientific™, as this item has been 
discontinued by the manufacturer, new Thermo Scientific™ 14P02 (DCS-240), Catalog # 
MA5–14260), MET polyclonal antibody (1:50, Met (D1C2) XP® Rabbit mAb #8198, Cell 
Signaling), Phospho-Met (Tyr1234/1235) (1:100, (D26) XP® Rabbit mAb #3077 Cell 
Signaling), MET(1:100, Met (C-28): sc-161, Santa Cruz), γH2AX (1:100, Phospho-Histone 
H2A.X (Ser139) (20E3) Rabbit mAb 9718, Cell signaling), ATR (1:100, clone C-1, 
sc-515173, Santa Cruz), AR (1:100, N-20, sc-816, Santa Cruz), BRCA1(1:100 (D-9): 
sc-6954, Santa Cruz), Ubiquitin (1:200, P4D1, sc-8017, Santa Cruz), HSP90 (1:100, 4F10, 
sc-69703) and β-Catenin (1:100, β-Catenin (D10A8) XP® Rabbit mAb #8480, Cell 
Signaling). For IB, cell lysates were prepared in NP40 cell lysis buffer (ThermoFisher), and 
subjected to a standard procedure of SDS-PAGE and antibody detection (1:1000, except 
special note). Additional antibodies list except IF, used for Western blotting were: mouse 
monoclonal anti-β-actin (AC-74, 1:5000 dilution, Catalog# A5316, Sigma Sigma), p14ARF 
(14P02, 1:750, new Thermo Scientific™ 14P02 (DCS-240), Catalog # MA5–14260), PARP 
(1:1000, #9542, Cell Signaling), Caspase 3 (1:1000, E-8, sc-7272, Santa Cruz), and MET 
(D1C2, 1:1000, #8198, Cell Signaling). For IP assay, cellular proteins were extracted by IP 
lysis buffer (Thermo Fisher), followed by immunoprecipitation with antibody of MET (C28, 
sc-161, Santa Cruz), and subjected to immunoblotting.
4. Signaling pathway reanalysis of microarray data
The gene expression profiles dataset of Pten/Trp53/p19Arf triple knockout mice (19) were 
used for reanalysis of ARF regulated signaling pathways as described previously (20) and 
genes expressed differently were analyzed by pathways using DAVID tools (https://
david.ncifcrf.gov/), with Mus musculus as the species background (47–50).
5. Prostate tissue microarrays (TMA)
Human prostate tissue microarrays were performed using paraffin-embedded normal 
prostate tissue (n=5) and PCa samples (n=35) (US Biomax) with information on the stage, 
Gleason’s score and grade (40 cases/80 cores, Catalog# PR808, informed consent was 
managed by Biomax.) which was approved by institutional committee with the aid of 
morphology core facility at Meharry Medical College. Tissue sections were stained with 
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antibodies against p14ARF (4C6/4, 1:50, p14ARF (4C6/4, 1:50, Catalog #2407, Cell 
Signaling) and MET (C28, sc-161, 1:500, Santa Cruz). The intensity of the staining was 
investigated blindly and graded as reported previously (51). The proportion and intensity 
scores were combined (0–8 range) (51). The correlation between MET and ARF levels were 
analyzed based on their combined scores.
6. Statistical analysis
All data were evaluated using two-tailed Student’s t-test unless otherwise stated, and values 
of p≤0.05, or p<0.01 were considered statistically significant assuming similar variation but 
calculated and indicated in figures. For statistics in figure legend, **, p<0.01; *, p≤0.05. 
Experiments were performed with three repeats or triplicates with reproducible repeat.
7. C-dots synthesis, characterization, and calculation of binding to phosphory-Tyrosine
The mixture of soybean and ethylenediamine (1:4) (Sigma Aldrich®) with water were heated 
at 200 oC for 5h. After centrifuge, the supernatant was collected by evaporating the water in 
vacuo using rotavap, followed by wash with methanol. The final solid product was obtained 
by heating in oven at 80oC for 24 h.
A SmartSPM 100 scanning probe microscope (AIST-NT) in non-contact mode was used to 
characterize the morphology and particle size of the carbon dots using high accuracy HA-
NC “etalon” probes (cantilever frequency 140 kHz) at a scan rate of 1 Hz. The functional 
groups distributed on the surface of c-dots were characterized using a FTIR spectrometer. 
The FTIR absorbance was recorded in the range of 400 cm−1 to 4000 cm-1. Calculation of 
C-dots binding to phosphory-Tyrosine was performed as described in details in supplemental 
methods (32).
8. Comet, ROS and Luciferase reporter assay
The PC3 cells were treated by carbon nanodots at 0.1 mg/ml for 2hrs followed by the comet 
and ROS assay. For comet assay, cells were subjected to treatment as protocol of the 
following (https://www.sigmaaldrich.com/life-science/cell-biology/cancer-research/learning-
center/cancer-research-protocols/comet-assay.html; http://www.cometassayindia.org). 
Briefly, trypsinized cells went through neutralization with DMEM medium and were diluted 
to 0.5×106 cells/ml with 1xPBS. Next, 0.5% low-melting agarose was melted, cooled for 20 
min at room temperature and then kept in the Thermoblocker at 37°C followed by mixing 
with diluted cells (50μl low-melting agarose: 20μl diluted cells) at 37°C. The solution was 
immediately transferred to anti-frost glass slides followed by covering by 1% agarose on 
top. The slides were finally put into the chamber protected from light with lysate buffer for 
15–20 hrs at 4°C. Following steps include electrophoresis in running buffer (pH 11.0, 300 
mM NaOH / 1 mM EDTA) for 50 min (20 min without running and 30 min at 24V, 100mA), 
washing with neutralization buffer for 5 min, washing by ddH2O for 1 min, and staining 
with ethidium bromide [2μg/ml] for 30 sec. Samples were kept under low light conditions. 
In addition, to avoid background noise running buffer solutions were freshly prepared. 
Finally, samples were visualized under Fluorescent microscope and analyzed using Comet 
Score software. ROS assay was performed based on the protocol of the manufacture using 
Invitrogen™ Total Reactive Oxygen Species (ROS) Assay Kit 520 nm (Invitrogen). Cells 
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were seeded on a black 96-well plate with clear bottom (1000cells/100μl/well) in phenol red 
free medium for overnight. CM-H2DCFDA dye was used for staining cells and the plate 
with samples were analyzed on a Cytation 5 (BioTek) imaging and Synergy H1 microplate 
reader. The Dual-Luciferase® Reporter (DLR™) Assay System kit (E1910, Promega) was 
used for MMP7 promoter-reporter assay. Cells were transfected as reported previously and 
assay was performed based on the protocol of manufacture (https://worldwide.promega.com/
resources/protocols/technical-manuals/0/dual-luciferase-reporter-assay-system-protocol/ )
9. Cell line and cell culture
Cells were cultured in medium of RPMI1640 or DMEM with 10% FBS and antibiotics. 
Most cell lines were purchased from ATCC within 1–2 years. C4–2B cells were purchased 
from MD Anderson Cancer center with authenticated report. LAPC4 cell line was a gift 
provided by Memorial Sloan Kettering Cancer Center. Others are mentioned in 
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Figure 1. Array analysis and genetically engineering mouse model identified that Met requires 
p19Arf in CRPC.
(A) Microarray reanalysis identified that ARF regulates MET pathway. (B-D) IHC analysis 
of Met protein expression in mouse prostate tissues (B) or recurrent prostate tumors (C-D) 
In Pten/Trp53 mutant mice, p19Arf deletion decreases the recurrent growth of prostate 
tumors of castrated Pten/Trp53 mutant mice at 4–6 months of age (C). Data are indicated by 
individual dots with analysis of p value. Nuclear MET and nuclear β-Catenin expression 
decreases upon p19Arf deletion (D).
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Figure 2. MET interacts with ARF in androgen insensitive PCa cells and correlates with ARF in 
human PCa specimens.
(A) IF images show co-localizations of ARF and MET in PC3 cells. (B) Co-IP assay shows 
ARF associates with MET in nuclear extracts from PC3 cells. (C) Concurrent knockdown of 
ARF and MET decreases PC3 cell growth. (D) A diagram shows the plasmid construct 
contains different domains. (E) IF images show MET deletion mutant translocases into 
nucleus upon ARF overexpression in androgen insensitive C4–2B cells. (F) MET deletion 
mutant promotes C4–2B cells proliferation upon ARF overexpression. C4–2B cells were 
viral infected by construct expressing different genes as indicated and cell proliferation 
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analysis was performed by WST-1 assay. (G) Elevated expression of ARF in different stages 
of tumors compared to normal prostate tissues. (H) IHC staining on ARF and MET 
expression in PCa samples. (I) ARF correlates with MET expression in PCa samples. Data 
are representative of averages+ SD (standard deviation).
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Figure 3. MET requires ARF for stabilization and recruitment of β-Catenin.
(A) knockdown of ARF decreases MET levels in PC3 and DU145 cells. (B) ARF 
knockdown decreases MET folding and turnover. (C) ARF knockdown increases 
colocalization of MET and Ubiquitin (Ub). (D) ARF overexpression decreases 
ubiquitination of MET. (E) IF images show ARF knockdown increases membrane 
localization of β-Catenin but decreases nuclear β-Catenin. (F) Co-IP assay shows ARF 
knockdown disrupts MET and β-Catenin association to decrease MET and β-Catenin 
expression. (G) MET increases β-Catenin degradation in stably expressing nMET and 
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mMET C4–2B cells which we described previously (13). (H) nMET induces transcription of 
β-Catenin target gene MMP7. Data are representative of averages+ SD (standard deviation).
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Figure 4. nMET requires ARF in drug resistance.
(A-C) IF images show MET inhibitor Crizotinib (A,B) or doxorubicin (DOX) treatment 
induces MET nuclear accumulation which depends on HSP90 (C) and ARF (B). PC3 cells 
with knockdown of ARF or control were treated with Crizotinib at 100nM or DOX at 1μM 
for 24hrs followed by Immunofluorescence Microscopy. (D). ARF and MET knockdown 
induces DNA damage response and decrease cell resistance to DOX. Data are representative 
of averages+ SD (standard deviation).
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Figure 5. Androgen receptor interrupts ARF/MET axis.
(A) AR inversely correlates with MET in prostate cancer cell lines. ARF levels were used as 
reference control based on our previous report (20). (B) ARF, MET and its signaling 
proteins β-Catenin, SOX9 co-upregulation by androgen depletion in LAPC4 cells. LAPC4 
cells were cultured in cFBS to deplete androgen for 6 days and regular FBS as control. (C) 
AR inversely correlates with MET in the prostate sphere. (D) ARF knockdown mediated 
MET downregulation is cytosolic MET-dependent. C, cytosolic lysates; N, nuclear lysates. 
(E) ARF knockdown mediated MET downregulation is androgen-dependent and is 
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interrupted by AR activation. (F) AR overexpression and activation disrupts ARF and MET 
interactions. PC3 cells were transfected by AR and stimulated by DHT at 15nM for 24hrs. 
(G) ARF inducible expression in LNCaP cells increases androgen independent cell growth. 
GFP fusion ARF expression is detected by GFP expression by imaging (left panel) and cell 
growth were detected by crystal violet staining (right panel). (H) Nuclear MET stimulates 
LNCaP cells migration independent on androgen but mMET dependents on androgen. (I) 
AR correlates with DNA repair protein BRCA1 in nucleus. (J) ARF knockdown increases 
BRCA1 nuclear localization. (K) AR, nMET, and ARF regulate ATM and PARP but not 
caspase 3 investigated by western blot. Data are representative of averages+ SD (standard 
deviation).
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Figure 6. nMET phosphorylation is sustained by ARF and is abolished by carbon nanodots.
(A-B) Stable ARF knockdown decreases nMET-mediated cell invasion and cell 
proliferation. (C-D) Stable ARF knockdown decreases nMET expression and 
phosphorylation. (E) nMET is phosphorylated protein. (F-G) C-dots abolish nMET and 
phosphorylated nMET levels in PC3 cells. (H) FT-IR spectra of c-dots. (a): experimental FT-
IR spectrum of c-dots. (b): Calculated IR spectrum of protonated acetamide based on 
geometry in Figure 8 AnH+(B); (I): FT-IR spectra of phosphorylated tyrosine before and 
after addition of c-dots (a): FT-IR spectrum of phosphorylated tyrosine (b): calculated IR 
Xie et al. Page 25
Oncogene. Author manuscript; available in PMC 2019 June 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
spectrum of phosphorylated tyrosine (c): FT-IR spectrum of phosphorylated tyrosine with 
the addition of c-dots (d): calculated IR spectrum of phosphorylated tyrosine and acetamide 
complex in Figure 8A (e) calculated IR spectrum of phosphorylated tyrosine and acetamide 
complex in Figure 8B (f) calculated IR spectrum of phosphorylated tyrosine and acetamide 
complex in Figure 8C (g) calculated IR spectrum of phosphorylated tyrosine and acetamide 
complex in Figure 8D; (J) FT-IR spectra of total protein extracted from PC3 cell (a) FT-IR 
spectra of total protein extracted from PC3 cell without c-dots (b) FT-IR spectra of total 
protein extracted from PC3 cell with the addition of c-dots. (K) Optimized structure for 
acetamide w/o protonated and phosphorylated tyrosine at different degrees of protonation. 
Legend of colours: white (H), grey (C), blue (N), red (O), and orange (P). Data are 
representative of averages+ SD (standard deviation).
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Figure 7. Carbon nanodots sensitize PCa cells to MET inhibitor.
(A) C-dots induce DNA damage response in DU145 cells at dose of 0.1mg/ml. (B-C) C-dots 
induce more DNA damage response and ROS generation in PC3 cells with MET inhibitor 
crizotinib. Cells were treated by c-dots at 0.1mg/ml with or without 10μM crizotinib 
followed by comet or ROS assay. (D) Western blot showing C-dots at low dose of 0.025 
mg/ml enhance DNA damage response, cleaved PARP, and decreased MET levels in PC3 
cells with MET inhibitor crizotinib. (E) C-dots induce high molecular weight protein 
ubiquitination in PC3 cells. (F-H) C-dot or DOX increases efficacy of MET inhibitor on PCa 
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cell growth. (I) C-dot or DOX increases efficacy of MET inhibitor on DNA damage 
response. Data are representative of averages+ SD (standard deviation).
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Figure 8. Optimized structures for the complexes formed between acetamide w/o protonated and 
phosphorylated tyrosine.
(A) non-protonated acetamide and Tyr- Tyr-OPO3H-. (B) Protonated acetamide and Tyr-
OPO3H-, where the involved oxygens on Tyr-OPO3H- are both not protonated. (C) 
Protonated acetamide and phosphorylated tyrosine, where the protonated C=O on acetamide 
interacts as a proton donor with the protonated P-O on Tyr-OPO3H-. (D) Protonated 
acetamide and Tyr-OPO3H-, where the protonated C=O on acetamide interacts as an 
electron lone pair donor with the protonated P-O on Tyr-OPO3H-.
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